Coridea recognized an unmet clinical need in the area of Contrast-Induced Nephropathy (CIN) — a form of acute renal failure caused by exposure to contrast media during image-guided cardiology and radiology procedures. Coridea discovered that a balanced high volume infusion of IV fluid flushes the patient’s kidneys and reduces damage from radiocontrast. The device based on Coridea’s discovery was named RenalGuard. The company recently spun out Reprieve Cardiovascular, which is exploring the use of this technology to treat patients with Acute Failure.
Reprieve Cardiovascular
